HBV感染對淋巴瘤患者自體外周血造血干細(xì)胞采集及植入的影響
發(fā)布時間:2018-08-13 14:49
【摘要】:目的:探討淋巴瘤合并HBV感染對自體外周血造血干細(xì)胞采集及移植后造血重建的影響。方法:收集2006年1月至2014年10月西安交通大學(xué)醫(yī)學(xué)院第一附屬醫(yī)院40例行自體移植的淋巴瘤患者的臨床資料進(jìn)行回顧性分析及隨訪。40例患者中8例合并有HBV感染,32例未合并HBV感染,對合并HBV感染者給予預(yù)防性應(yīng)用核苷類似物抗乙肝病毒治療,觀察兩組患者采集的單個核細(xì)胞數(shù)及CD34~+細(xì)胞數(shù)、造血重建和總生存率及疾病無進(jìn)展生存率間的差異。結(jié)果:40例患者的自體外周血造成血干細(xì)胞的采集均達(dá)標(biāo),兩組患者采集的單個核細(xì)胞數(shù)及CD34~+細(xì)胞數(shù)無顯著性統(tǒng)計學(xué)差異,8例合并HBV感染的患者在移植中均無HBV的再激活。至隨訪結(jié)束,合并HBV感染患者1年、3年及5年總生存率和疾病無進(jìn)展生存率分別為100%、85.7%和57.1%及100%,80%和53.3%,未合并HBV感染患者1年、3年及5年總生存率和疾病無進(jìn)展生存率分別為100%、88.9%,82.1%及90%,90%和90%。結(jié)論:HBV感染對自體外周血造血干細(xì)胞的采集和植入可能無影響。預(yù)防性應(yīng)用核苷類似物可有效預(yù)防HBV再激活,且對自體外周血造血干細(xì)胞采集及植入無影響。
[Abstract]:Objective: to investigate the effect of lymphoma combined with HBV infection on autologous peripheral blood stem cell collection and hematopoietic reconstitution after transplantation. Methods: the clinical data of 40 cases of lymphoma with autologous transplantation in the first affiliated Hospital of Xi'an Jiaotong University Medical College from January 2006 to October 2014 were retrospectively analyzed and 8 of the 40 patients with HBV infection were followed up. 32 cases were not complicated with HBV infection. In order to observe the difference of mononuclear cell count, CD34 ~ cell number, hematopoietic reconstitution and overall survival rate and disease progression survival rate in patients with HBV infection, the prophylactic application of nucleoside analogue against hepatitis B virus (HBV) was performed in the two groups. Results there was no significant difference in the number of mononuclear cells and CD34 ~ cells between the two groups. There was no significant difference in the number of mononuclear cells and CD34 ~ cells between the two groups. There was no reactivation of HBV in 8 patients with HBV infection. Up to the end of the follow-up, The 1-year, 3-year and 5-year overall survival rate and disease progression-free survival rate in patients with HBV infection were 100% and 57.1% and 100% and 53.3%, respectively. The 1-year, 3-year and 5-year overall survival rates and disease-free survival rates in patients with HBV infection were 82.1% and 9090%, respectively. Conclusion the infection of HBV may have no effect on the collection and implantation of autologous peripheral blood stem cells. Prophylactic application of nucleoside analogue can effectively prevent HBV reactivation and has no effect on autologous peripheral blood stem cell collection and implantation.
【作者單位】: 西安交通大學(xué)醫(yī)學(xué)院第一附屬醫(yī)院血液內(nèi)科;
【分類號】:R733.1;R512.62
本文編號:2181306
[Abstract]:Objective: to investigate the effect of lymphoma combined with HBV infection on autologous peripheral blood stem cell collection and hematopoietic reconstitution after transplantation. Methods: the clinical data of 40 cases of lymphoma with autologous transplantation in the first affiliated Hospital of Xi'an Jiaotong University Medical College from January 2006 to October 2014 were retrospectively analyzed and 8 of the 40 patients with HBV infection were followed up. 32 cases were not complicated with HBV infection. In order to observe the difference of mononuclear cell count, CD34 ~ cell number, hematopoietic reconstitution and overall survival rate and disease progression survival rate in patients with HBV infection, the prophylactic application of nucleoside analogue against hepatitis B virus (HBV) was performed in the two groups. Results there was no significant difference in the number of mononuclear cells and CD34 ~ cells between the two groups. There was no significant difference in the number of mononuclear cells and CD34 ~ cells between the two groups. There was no reactivation of HBV in 8 patients with HBV infection. Up to the end of the follow-up, The 1-year, 3-year and 5-year overall survival rate and disease progression-free survival rate in patients with HBV infection were 100% and 57.1% and 100% and 53.3%, respectively. The 1-year, 3-year and 5-year overall survival rates and disease-free survival rates in patients with HBV infection were 82.1% and 9090%, respectively. Conclusion the infection of HBV may have no effect on the collection and implantation of autologous peripheral blood stem cells. Prophylactic application of nucleoside analogue can effectively prevent HBV reactivation and has no effect on autologous peripheral blood stem cell collection and implantation.
【作者單位】: 西安交通大學(xué)醫(yī)學(xué)院第一附屬醫(yī)院血液內(nèi)科;
【分類號】:R733.1;R512.62
【相似文獻(xiàn)】
相關(guān)期刊論文 前5條
1 謝蕾;張忠東;喻劍華;時代強(qiáng);張永樂;;艾滋病合并淋巴瘤患者的臨床分析[J];醫(yī)學(xué)研究雜志;2014年06期
2 張祥忠;何敏;彭愛華;童秀珍;李娟;陳運(yùn)賢;;惡性淋巴瘤患者乙型肝炎病毒感染狀況分析[J];國際內(nèi)科學(xué)雜志;2008年02期
3 許崇安;邢麗麗;李艷;蘇賀;鄧娜;劉云鵬;;HBV感染與淋巴瘤患者化療后肝功能損害的相關(guān)性分析[J];中國腫瘤臨床;2009年21期
4 Дранкин ДИ Заяц НА ,龍寶光;傳染性單核細(xì)胞增多癥的流行病學(xué)[J];國外醫(yī)學(xué).流行病學(xué)傳染病學(xué)分冊;1982年05期
5 ;[J];;年期
相關(guān)碩士學(xué)位論文 前3條
1 李卓;139例淋巴瘤患者乙型肝炎病毒感染情況的臨床分析[D];蘭州大學(xué);2016年
2 唐楊;156例淋巴瘤患者乙型肝炎病毒感染率臨床分析[D];吉林大學(xué);2011年
3 白洋祿;乙型肝炎病毒感染與淋巴瘤關(guān)系的研究[D];廣西醫(yī)科大學(xué);2014年
,本文編號:2181306
本文鏈接:http://www.sikaile.net/yixuelunwen/chuanranbingxuelunwen/2181306.html
最近更新
教材專著